We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: tislelizumab
MedXY News
EnglishTag

tislelizumab

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma
newsimmunotherapynasopharyngeal carcinoma

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

By MedXY|Mar 9, 2026

The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signat

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma
newsimmunotherapynasopharyngeal carcinoma

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma

By MedXY|Mar 2, 2026

Long-term results from the RATIONALE-309 trial show tislelizumab plus chemotherapy significantly improves survival in recurrent or metastatic nasopharyngeal carcinoma, establishing a durable therapeutic standard and identifying B-cell signa

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes
newsHNSCCimmunotherapy

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes

By MedXY|Jan 13, 2026

A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcino

Conversion Therapy with Tislelizumab, Lenvatinib, and GEMOX in Unresectable Locally Advanced Biliary Tract Cancer: The ZSAB-TransGOLP Phase 2 Study
GastroenterologyBiliary tract cancerGEMOX

Conversion Therapy with Tislelizumab, Lenvatinib, and GEMOX in Unresectable Locally Advanced Biliary Tract Cancer: The ZSAB-TransGOLP Phase 2 Study

By MedXY|Oct 15, 2025

The ZSAB-TransGOLP study demonstrates the promising efficacy and manageable safety of combining tislelizumab, lenvatinib, and GEMOX chemotherapy as a conversion therapy for unresectable locally advanced biliary tract cancer, achieving a 63%

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities